Well, maybe now we know why GILD hasn’t gone aft
Post# of 145746
Hope I’m wrong but this Could be trouble. Forty Seven partnering with GILD becomes a massive, well funded competitor in cancer - with a novel monoclonal antibody treatment.
Obviously there are other high quality competitors chasing the same goal - and these guys seem light years ahead in terms of money, connections, etc.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)